Trial
NCT01589029
A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
PD Dr. med. Stephan Michels
Collaborators
Novartis; University Hospital, Zürich
Condition
Proliferative Diabetic Retinopathy
Intervention
CANAKINUMAB (ILARIS®)
Why stopped
The results of the interim analysis showed that the primary endpoint was not met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-24